Table 1.

Demographics and Clinical Characteristics, Psychosocial Status, and Quality of Life at the Time of the Initial Survey (2005): Comparison of Patients Who Did and Did Not Participate in the Follow-Up Survey (2010)

Baseline Demographic or Clinical Characteristic	Participants(n = 566)		Nonparticipants, Assumed Living (n = 144)a		Pb	Deceased at Follow-Up(n = 176)		Pc
	No.	%	No.	%		No.	%
Demographics
Female sex	294	51.9	78	54.2	.633	79	44.9	.102
White race	494	87.3	108	75.0	< .001	155	88.1	.783
Income < $30,000	113	22.2	53	41.4	< .001	59	37.8	< .001
College or postgraduate degree	242	43.6	50	35.7	.091	45	26.6	< .001
Married or living with a partner	452	80.4	96	68.1	.001	124	71.3	.011
Age, years					< .001			< .001
Mean	62.4		56.7			69.5
SD	12.4		15.6			11.7
Clinical characteristicsd
Had an indolent type of lymphoma	270	50.3	76	55.9	.243	99	60.7	.019
Was diagnosed at stage > I	339	68.1	76	62.3	.224	104	71.2	.467
Systemic treatment statuse
Received chemotherapy only	257	45.4	72	50.0	.324	74	42.1	.433
Received biologic therapy only	29	5.1	7	4.9	.898	5	2.8	.206
Received chemotherapy and biologic therapy	108	19.1	16	11.1	.025	39	22.2	.371
Received a transplantation	90	15.9	15	10.4	.098	30	17.1	.719
Did not receive systemic treatment	82	14.5	34	23.6	.008	28	15.9	.643
Was currently receiving treatment	58	10.4	22	15.6	.083	37	21.8	< .001
Had active diseasef	47	9.1	20	15.9	.027	42	28.2	< .001
Had a recurrence of disease	184	33.2	39	28.7	.317	70	42.7	.001
Time since diagnosis, years					.156			.747
Mean	10.4		9.5			10.2
SD	7.1		6.5			7.3
Comorbidity scoreg					.166			< .001
Mean	5.2		5.8			6.7
SD	4.5		5.5			5.2
Had a second primary cancer	71	12.7	16	11.4	.673	33	19.4	.027
Lymphoma symptom scoreh					.001			< .001
Mean	49.3		46.3			44.4
SD	8.8		11.5			11.0
Psychosocial status scores
Social Supporti					.079			.514
Mean	83.4		80.7			84.3
SD	16.0		17.1			17.3
IOC Negative Impactj					.080			.003
Mean	2.2		2.3			2.4
SD	0.7		0.9			0.8
IOC Positive Impactk					.978			.181
Mean	3.5		3.5			3.4
SD	0.8		0.8			0.8
Quality-of-life scores
SF-36 PCSl					.033			< .001
Mean	47.2		45.0			39.1
SD	10.2		11.3			11.5
SF-36 MCSm					< .001			< .001
Mean	50.4		45.7			45.7
SD	10.7		11.3			11.7

Abbreviations: IOC, Impact of Cancer; MCS, Mental Component Score; PCS, Physical Component Score; SD, standard deviation; SF-36, Medical Outcomes Study Short Form-36.

^aAssumed living; calculated as total initial sample (N = 866) minus participants (n = 566) minus deceased (n = 176).

^bP value for comparison of participants and nonparticipants, based on χ² for percentages and t test for means.

^cP value for comparison of participants and decedents, based on χ² for percentages and t test for means.

^dDoes not include changes between baseline and follow-up surveys.

^eSystemic treatment at initial survey includes chemotherapy, biologic therapy, and bone marrow or stem-cell transplantation.

^fWas not in remission or cured of non-Hodgkin lymphoma.

^gSelf-Administered Comorbidity Questionnaire; possible score range, 0 to 42.

^hFunctional Assessment of Cancer Therapy–Lymphoma module; 15 items, possible score range, 0 to 60. Lower scores indicate greater symptoms.

ⁱMedical Outcomes Study Social Support total score; possible score range, 0 to 100; higher scores indicate higher support.

^jIOC Negative Summary score; possible score range, 1 to 5; higher scores indicate greater negative impacts.

^kIOC Positive Summary score; possible score range, 1 to 5; higher scores indicate greater positive impacts.

^lThe median population score is 50; a higher score indicates better functioning.

^mThe median population score is 50; a higher score indicates better functioning.